Life Biosciences raises $50M series B for aging-related R&D

Life Biosciences LLC (Boston, Mass.) raised $50 million in an upsized series B round, which Life Bioscience and its "daughter" companies will use to develop therapeutics against age-related decline. Life Biosciences said the round surpassed its $25 million target.

Life Biosciences is targeting the molecular mechanisms linked to age-related decline through its six daughter companies, including senescence company Senolytic Therapeutics, mitochondrial company Continuum Biosciences, peptide company Spotlight Biosciences and autophagy company Selphagy Therapeutics...